Imbria Pharmaceuticals Inc.
- Address
- 265 Franklin Street Suite 1702
Sponsor Overview
Specializations
Cardiomyopathy Research
Imbria Pharmaceuticals Inc. focuses on non-obstructive hypertrophic cardiomyopathy, with particular attention to patients living with symptomatic disease and impaired health status.
- Hypertrophic cardiomyopathy
- Non-obstructive cardiomyopathy
- Symptom burden
The sponsor’s clinical activity is centered on cardiac conditions that affect daily functioning and quality of life.
Cardiovascular Therapeutics
The company’s research interest extends to cardiovascular medicine, with a specific therapeutic emphasis on improving clinical outcomes in heart muscle disease.
- Cardiac function
- Myocardial disease
- Functional capacity
This area reflects a targeted focus on treatment options for patients with persistent cardiac symptoms.
Symptom Management in Heart Disease
Research activity is directed toward the treatment of symptomatic patients, with attention to changes in day-to-day well-being and disease-related limitations.
- Patient-reported health status
- Exercise tolerance
- Breathlessness
The therapeutic interest is closely tied to the clinical burden experienced by individuals with cardiac hypertrophy.
Investigational Cardiac Treatment Development
Imbria Pharmaceuticals Inc. is engaged in the development of an investigational therapy for nHCM, reflecting a focus on novel approaches in cardiac pharmacology.
- Ninerafaxstat
- Placebo-controlled evaluation
- Safety and efficacy
The research portfolio is concentrated on a single rare heart disease indication within specialty cardiovascular care.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| Efficacy and Safety Evaluation of Ninerafaxstat in Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy: A Randomized, Double-Blind, Placebo-Controlled Phase 2b Trial |  Austria Belgium France Germany Italy Poland Portugal Spain The Netherlands | Recruiting |
Data & Insights
This sponsor works with 0 molecules, of which 0 are not being studied by other sponsors.
This sponsor has worked with 36 sites across their trial portfolio.
Therapeutic Focus
- 1.Cardiovascular Diseases1 trial359 other sponsors
Partnered Research Centres
36 centres- Address
- Ul. Rudolfa Weigla 5, 53-114 Wroclaw
- Address
- Meibergdreef 9, 1105 AZ Amsterdam
- Address
- Piazza Dell'ospedale Maggiore 3, 20162 Milan
- Address
- Via Sergio Pansini 5, 80131 Naples
- Address
- Largo Giovanni Alessandro Brambilla 3, 50134 Florence
- Address
- Carrer De La Feixa Llarga S/N, 08907 L'hospitalet De Llobregat
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Imbria Pharmaceuticals Inc..
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.